CNQX (Standard)

CNQX (Standard) is the analytical standard of CNQX. This product is intended for research and analytical applications. CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist[1]. CNQX blocks the expression of fear-potentiated startle in rats[5].

Product Specifications

CAS Number

[115066-14-3]

UNSPSC

12352100

Target

IGluR; Reference Standards

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Neurological Disease

Smiles

O=C1C(NC2=CC([N+]([O-])=O)=C(C#N)C=C2N1)=O

Molecular Formula

C9H4N4O4

Molecular Weight

232.15

References & Citations

[1]T Honoré, et al. Quinoxalinediones: Potent Competitive non-NMDA Glutamate Receptor Antagonists. Science. 1988 Aug 5;241 (4866) :701-3.|[2]Neuman RS, et al. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the hippocampus in vitro. Neurosci Lett. 1988 Sep 23;92 (1) :64-8.|[3]Alford S, et al. CNQX and DNQX block non-NMDA synaptic transmission but not NMDA-evoked locomotion in lamprey spinal cord. Brain Res. 1990 Jan 8;506 (2) :297-302.|[4]Pia Bäckström, et al. Attenuation of Cocaine-Seeking Behaviour by the AMPA/kainate Receptor Antagonist CNQX in Rats. Psychopharmacology (Berl) . 2003 Feb;166 (1) :69-76.|[5]Kim M, et al. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993 Jan;59 (1) :5-8.